The estimated Net Worth of Nick Pizzie is at least $1.58 Million dollars as of 18 November 2021. Mr. Pizzie owns over 955 units of Axsome Therapeutics Inc stock worth over $12,926 and over the last 6 years he sold AXSM stock worth over $0. In addition, he makes $1,569,840 as Chief Financial Officer at Axsome Therapeutics Inc.
Sign up
Mr. Pizzie AXSM stock SEC Form 4 insiders trading
Nick has made over 6 trades of the Axsome Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 955 units of AXSM stock worth $33,673 on 18 November 2021.
The largest trade he's ever made was buying 31,000 units of Axsome Therapeutics Inc stock on 19 June 2018 worth over $96,100. On average, Nick trades about 2,815 units every 83 days since 2018. As of 18 November 2021 he still owns at least 142 units of Axsome Therapeutics Inc stock.
You can see the complete history of Mr. Pizzie stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Nick Pizzie biography
Nick Pizzie CPA serves as Chief Financial Officer of the Company. Prior to joining Axsome, from May 2013 to May 2018, Mr. Pizzie was the Vice President and Chief Financial Officer of Pierre Fabre USA, the U.S. affiliate of Pierre Fabre. Previously, he was Senior Finance Director at Immucor. Prior to Immucor, he held positions of increasing responsibility in finance and accounting at Merck and Pfizer. Mr. Pizzie began his career at Arthur Andersen, where he served as staff auditor. He earned his Bachelor of Science in Accounting, Bachelor of Arts in Economics, and Master of Business Administration in Finance, and Supply Chain Logistics, from Rutgers University.
What is the salary of Nick Pizzie?
As the Chief Financial Officer of Axsome Therapeutics Inc, the total compensation of Nick Pizzie at Axsome Therapeutics Inc is $1,569,840. There are 2 executives at Axsome Therapeutics Inc getting paid more, with Herriot Tabuteau having the highest compensation of $4,715,750.
How old is Nick Pizzie?
Nick Pizzie is 45, he's been the Chief Financial Officer of Axsome Therapeutics Inc since 2018. There are 6 older and 6 younger executives at Axsome Therapeutics Inc. The oldest executive at Axsome Therapeutics Inc is David Marek, 55, who is the Chief Commercial Officer.
What's Nick Pizzie's mailing address?
Nick's mailing address filed with the SEC is C/O AXSOME THERAPEUTICS, INC., ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK, NY, 10007.
Insiders trading at Axsome Therapeutics Inc
Over the last 9 years, insiders at Axsome Therapeutics Inc have traded over $3,013,485 worth of Axsome Therapeutics Inc stock and bought 82,512 units worth $1,366,003 . The most active insiders traders include Roger Jeffs, Susan Mahony, and Mark Coleman. On average, Axsome Therapeutics Inc executives and independent directors trade stock every 114 days with the average trade being worth of $1,405,685. The most recent stock trade was executed by Mark E Saad on 11 September 2024, trading 11,016 units of AXSM stock currently worth $40,429.
What does Axsome Therapeutics Inc do?
axsome therapeutics is a biopharmaceutical company developing novel therapies for the treatment of cns disorders. axsome has a balanced portfolio of clinical development stage as well as research stage product candidates. the company is based in new york city.
What does Axsome Therapeutics Inc's logo look like?
Complete history of Mr. Pizzie stock trades at Axsome Therapeutics Inc
Axsome Therapeutics Inc executives and stock owners
Axsome Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Herriot Tabuteau,
Chairman of the Board, President, Chief Executive Officer, Founder -
David Marek,
Chief Commercial Officer -
Nick Pizzie,
Chief Financial Officer -
Dr. Herriot Tabuteau M.D.,
Founder, Chairman, CEO & Pres -
Mark L. Jacobson,
COO & Sec. -
Nick Pizzie CPA, M.B.A.,
Chief Financial Officer -
Roger Jeffs,
Lead Independent Director -
Mark Saad,
Independent Director -
Mark Coleman,
Independent Director -
Amanda Jones,
Senior Vice President - Clinical Research -
Cedric O'Gorman,
Senior Vice President - Clinical Development and Medical Affairs -
Mark Jacobson,
Chief Operating Officer -
Joseph Debrah-Afful CPA, M.B.A.,
Director of Fin. -
Kevin Laliberte Pharm.D.,
Exec. VP of Product Strategy -
Lori Englebert M.B.A.,
Sr. VP of Commercial & Bus. Devel. -
Dr. Amanda Jones Pharm.D.,
Sr. VP of Clinical Devel. -
Constance Ames,
Vice President, Finance -
Myrtle S Potter,
Director -
Randall Kaye,
Chief Medical Officer -
Hunter R. Murdock,
General Counsel -
John Golubieski,
Chief Financial Officer -
Susan Mahony,